PT2945967T - Polipéptido solúvel do recetor 3 do fator de crescimento de fibroblastos (fgfr3) para utilização na prevenção ou no tratamento de distúrbios de atraso de crescimento esquelético - Google Patents

Polipéptido solúvel do recetor 3 do fator de crescimento de fibroblastos (fgfr3) para utilização na prevenção ou no tratamento de distúrbios de atraso de crescimento esquelético

Info

Publication number
PT2945967T
PT2945967T PT147022065T PT14702206T PT2945967T PT 2945967 T PT2945967 T PT 2945967T PT 147022065 T PT147022065 T PT 147022065T PT 14702206 T PT14702206 T PT 14702206T PT 2945967 T PT2945967 T PT 2945967T
Authority
PT
Portugal
Prior art keywords
fgr3
polypeptide
prevention
treatment
factor receptor
Prior art date
Application number
PT147022065T
Other languages
English (en)
Original Assignee
Univ Toulouse 3 Paul Sabatier
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toulouse 3 Paul Sabatier, Inst Nat Sante Rech Med filed Critical Univ Toulouse 3 Paul Sabatier
Publication of PT2945967T publication Critical patent/PT2945967T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT147022065T 2013-01-16 2014-01-16 Polipéptido solúvel do recetor 3 do fator de crescimento de fibroblastos (fgfr3) para utilização na prevenção ou no tratamento de distúrbios de atraso de crescimento esquelético PT2945967T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Publications (1)

Publication Number Publication Date
PT2945967T true PT2945967T (pt) 2020-05-28

Family

ID=48289519

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147022065T PT2945967T (pt) 2013-01-16 2014-01-16 Polipéptido solúvel do recetor 3 do fator de crescimento de fibroblastos (fgfr3) para utilização na prevenção ou no tratamento de distúrbios de atraso de crescimento esquelético

Country Status (20)

Country Link
US (5) US20150344855A1 (pt)
EP (2) EP2945967B1 (pt)
JP (3) JP2016506914A (pt)
KR (3) KR20160002681A (pt)
CN (1) CN105121464B (pt)
AU (2) AU2013373679A1 (pt)
CA (2) CA2898415A1 (pt)
DK (1) DK2945967T3 (pt)
EA (2) EA201591324A1 (pt)
ES (1) ES2796743T3 (pt)
HK (1) HK1217959A1 (pt)
HU (1) HUE049556T2 (pt)
IL (2) IL239810A0 (pt)
MX (2) MX2015009142A (pt)
PE (1) PE20151664A1 (pt)
PL (1) PL2945967T3 (pt)
PT (1) PT2945967T (pt)
SG (2) SG11201505488XA (pt)
SI (1) SI2945967T1 (pt)
WO (2) WO2014111744A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
DK3242888T3 (da) 2015-01-07 2021-02-15 Pfizer Opløselige fgfr3-atrapper til behandling af skeletvækstforstyrrelser
KR101981774B1 (ko) * 2016-04-25 2019-05-27 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체
SI3481859T1 (sl) 2016-07-07 2022-07-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe
AU2018335837A1 (en) * 2017-09-20 2020-04-23 Centre National Recherche Scientifique Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
DK0836380T3 (da) * 1995-06-12 2002-04-22 Yeda Res & Dev FGF9 som en specifik ligand for FGFR3
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
DK1522590T3 (da) 2000-06-28 2009-12-21 Glycofi Inc Fremgangsmåde til fremstilling af modificerede glykoproteiner
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
WO2002050246A2 (en) * 2000-12-18 2002-06-27 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
DK1718756T3 (da) 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
EP1910542B1 (en) * 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
CA2664921A1 (en) 2006-09-28 2008-04-03 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
JP5787757B2 (ja) 2008-08-04 2015-09-30 ファイブ プライム セラピューティックス インコーポレイテッド Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
SG174904A1 (en) 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
CA2780457A1 (en) 2009-11-13 2011-05-19 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
MX2012008222A (es) 2010-01-14 2012-08-17 Univ Yale Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas.
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
EP2658979B1 (en) * 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN104093415B (zh) 2011-10-24 2017-04-05 哈洛齐梅公司 抗乙酰透明质酸剂疗法的同伴诊断剂及其使用方法
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
WO2014018673A2 (en) 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
EP2877209A1 (en) 2012-07-27 2015-06-03 Genentech, Inc. Methods of treating fgfr3 related conditions
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
DK3242888T3 (da) 2015-01-07 2021-02-15 Pfizer Opløselige fgfr3-atrapper til behandling af skeletvækstforstyrrelser
SI3481859T1 (sl) 2016-07-07 2022-07-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe
AU2018335837A1 (en) 2017-09-20 2020-04-23 Centre National Recherche Scientifique Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides

Also Published As

Publication number Publication date
KR20160002681A (ko) 2016-01-08
US11814654B2 (en) 2023-11-14
SG11201505488XA (en) 2015-08-28
JP6995069B2 (ja) 2022-02-04
EP2945967B1 (en) 2020-04-15
US10724014B2 (en) 2020-07-28
CN105121464A (zh) 2015-12-02
US20210032607A1 (en) 2021-02-04
IL239996A0 (en) 2015-08-31
AU2013373679A1 (en) 2015-08-13
CN105121464B (zh) 2021-05-07
PL2945967T3 (pl) 2020-11-16
CA2896978A1 (en) 2014-07-24
CA2898415A1 (en) 2014-07-24
EP2945967A1 (en) 2015-11-25
AU2014206844A1 (en) 2015-07-16
MX2015009142A (es) 2015-11-06
DK2945967T3 (da) 2020-07-13
HK1217959A1 (zh) 2017-01-27
US20150353624A1 (en) 2015-12-10
SG11201505140XA (en) 2015-07-30
PE20151664A1 (es) 2015-11-28
HUE049556T2 (hu) 2020-09-28
WO2014111744A1 (en) 2014-07-24
US11702642B2 (en) 2023-07-18
EP3736285A1 (en) 2020-11-11
KR20210054026A (ko) 2021-05-12
SI2945967T1 (sl) 2020-10-30
JP2019107006A (ja) 2019-07-04
US20200199545A1 (en) 2020-06-25
KR102249454B1 (ko) 2021-05-07
WO2014111467A1 (en) 2014-07-24
US20150344855A1 (en) 2015-12-03
JP2016506914A (ja) 2016-03-07
ES2796743T3 (es) 2020-11-30
EA201591324A1 (ru) 2016-01-29
MX2019013857A (es) 2020-01-20
KR20150122136A (ko) 2015-10-30
EA201591055A1 (ru) 2016-04-29
IL239810A0 (en) 2015-08-31
US20210032608A1 (en) 2021-02-04
JP2016506912A (ja) 2016-03-07

Similar Documents

Publication Publication Date Title
HK1217959A1 (zh) 用於預防或治療骨胳生長遲緩病症的可溶性成纖維細胞生長因子受體 多肽
HRP20211272T8 (hr) 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda
IL245101B (en) Derivatives of 1,4-cyclohexylamine and processes for their preparation
PT3811943T (pt) Composto para uso no tratamento de distúrbios oculares
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
HK1206615A1 (en) Mglu2/3 antagonists for the treatment of autistic disorders mglu2/3
RS65553B1 (sr) Faktor 1 protein za upotrebu u lečenju ili prevenciji bolesti
IL248855B (en) S-pyralindole and its pharmaceutically acceptable salts for use in medicine
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
SI3049100T1 (sl) Modificirani faktorji rasti fibroblasta-1 za zdravljenje očesnih motenj
EP3648789C0 (en) MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY
IL254766B (en) A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome
GB201521442D0 (en) Polytpeptides and analogues thereof for use in the treatment of diabetes and bone disorders
EP2938198A4 (en) RECOMBINANT COLLAGEN 7 ADMINISTRATION FOR THE TREATMENT OF AGE-RELATED DISORDERS
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders